Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

This is a study testing a new drug called BMF-219, which is a menin inhibitor. Menin is a protein in the body that can help certain cancers grow. The study is for adults with specific types of cancer, like acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL), as well as some lymphomas and multiple myeloma. This is a Phase 1 study, which means it's the first time this drug is being tested in humans, to see how much of it can be safely given. Participants need to be 18 or older, have a confirmed diagnosis of their cancer, and must have tried other treatments without success. If you join, you might need to stop other cancer treatments. The study will check how well you do with the new medicine.

• Participants must be 18 years or older and have certain types of cancer.
• You should have tried other treatments that didn't work before joining.
• Both men and women must use birth control during the study and for 90 days after.

Before joining, you'll talk with doctors who will explain everything and answer your questions. 🤔